Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM159PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 200 | uM | 11057.145 | 1.0120 | 1.0062 | 3.8266 | |
| SUM185PE | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 12269.145 | 0.9705 | 0.8812 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 12269.145 | 0.9396 | 0.7609 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 12269.145 | 1.5347 | 3.7985 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 12269.145 | 1.0025 | 1.0101 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 12269.145 | 0.6533 | -0.1620 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 12269.145 | 1.5238 | 3.7292 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 12269.145 | 1.3564 | 2.7287 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 12269.145 | 0.6368 | -0.2047 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 12269.145 | 0.9780 | 0.9112 | 0.4894 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 10579.145 | 1.0180 | 1.0337 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 10579.145 | 0.9016 | 0.8149 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 10579.145 | 0.9163 | 0.8425 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 10579.145 | 0.9569 | 0.9190 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 10579.145 | 1.0715 | 1.1338 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 10579.145 | 0.9228 | 0.8548 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 10579.145 | 0.9427 | 0.8923 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 10579.145 | 0.8611 | 0.7382 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 10579.145 | 0.8903 | 0.7935 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 12098.145 | 0.9830 | 0.9652 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 12098.145 | 1.0163 | 1.0334 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 12098.145 | 1.0747 | 1.1532 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 12098.145 | 1.0900 | 1.1845 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 12098.145 | 0.9778 | 0.9546 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 12098.145 | 1.0898 | 1.1840 | 0.9769 |